FONAR Corp.

As of October 17, 2025, FONAR Corp. is fairly valued with a P/E ratio of 8, a Price to Book Value of 0.53, and an EV to EBITDA of 2.31, showing better performance than some peers despite a 5-year return of -27.06% compared to the S&P 500's 91.29%.

As of July 24, 2025, FONAR Corp. has shifted to a mildly bullish trend supported by the weekly MACD and moving averages, despite underperforming the S&P 500 with year-to-date returns of 2.44% compared to 12.22%.

As of July 21, 2025, FONAR Corp. is fairly valued with a P/E ratio of 8 and has underperformed the S&P 500 with a return of -10.86% over the past year, raising concerns about its future growth potential.

As of May 19, 2025, FONAR Corp. shows a mildly bearish trend with daily moving averages indicating bearishness, while weekly indicators suggest mild bullishness, but overall mixed signals reflect a lack of strong bullish momentum.

As of April 25, 2025, FONAR Corp. is considered an attractive investment due to its undervalued status with a P/E ratio of 8, a Price to Book Value of 0.53, and an EV to EBITDA ratio of 2.31, despite a year-to-date return of -6.77% compared to the S&P 500's 2.44%.

As of March 2022, FONAR Corp.'s management team includes Dr. Raymond Damadian as Chairman, Principal Financial Officer, and Treasurer, with Mrs. Claudette Chan as Secretary and Director, alongside independent directors Mr. Ronald Lehman, Mr. Charles O'Data, and Mr. Richard Turk.

FONAR Corp. designs, manufactures, and services MRI scanners, operating as a micro-cap company with recent net sales of $27 million and a net profit of $3 million. It has a market cap of $89.01 million and key metrics include a P/E ratio of 8.00 and a return on equity of 6.38%.

As of Jun 18, FONAR Corp. has a market capitalization of 89.01 million, with net sales of 103.01 million and a net profit of 10.96 million reported over the latest four quarters. As of Jun 24, the company has shareholder's funds of 165.97 million and total assets of 214.25 million.